Worth reading
41Recurring
Scored from 5 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
9.9
Year-on-year change in operating income (%)Wording
Conditional
How definitive the wording is.Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPNet Sales30,985¥ millionYear on year +2.0%Progress 21.8%
Operating profit4,592¥ millionYear on year +9.9%Progress 18.0%
Ordinary income4,867¥ millionYear on year +11.5%Progress 19.1%
Net income attributable to owners of the parent3,079¥ millionYear on year +8.8%Progress 17.4%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥113.97
Financial position at period-end
Total assets229,264¥ million
of which net assets 191,845 ¥ millionEquity ratio 83.7%vs. prior year-end -0.1pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Segment revenue
Physiological measuring equipment4,52614.6%+1.5%
Patient Monitoring Systems1,3014.2%-0.7%
Treatment equipment15,61250.4%+1.7%
Consumables and other products9,54630.8%+3.0%
Segment profit
Physiological measuring equipment58712.8%
Patient Monitoring Systems1944.2%
Treatment equipment2,54555.4%
Consumables and other products1,26527.6%
Regional sales
Domestic30,52998.5%
Overseas expansion4561.5%
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥142,000 million (YoY +1.6%)
Operating profit¥25,500 million (YoY -4.2%)
Ordinary income¥25,500 million (YoY -6.7%)
Net income¥17,700 million (YoY -5.8%)
Revision to Earnings ForecastNo
Annual Dividend Forecast¥230 → ¥230（0.0%）
Factors Behind Changes in Business Performance
Although sales of electrocardiograph-related products and automated hematology analyzers declined, sales from the rental business for home healthcare grew, and sales of consumables and other products also increased.
Disclosure regarding the going concern assumption
No applicable matters.
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew Not disclosed / Excluded Not disclosed / Company name Not disclosed / Material changes No
Impairment loss¥1 million
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets ¥0 million, Gain on sale of investment securities ¥78 million, Insurance surrender value ¥1 million / Extraordinary loss Loss on sale of fixed assets ¥0 million, Impairment Losses ¥1 million
Depreciation and amortization¥3,095 million
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingWhether applicable No / Subject person Not disclosed
Issued Shares at Period-End37,747,300 Shares
Treasury Shares at Period-End10,729,506 Shares
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥30,985 million (YoY +2.0%) |
| Operating profit | ¥4,592 million (YoY +9.9%) |
| Ordinary income | ¥4,867 million (YoY +11.5%) |
| Profit attributable to owners of the parent | ¥3,079 million (YoY +8.8%) |
| Net income per share | ¥113.97 |
| Equity ratio | End of the current fiscal period 83.7% / End of previous period 83.8% |
| Total assets | ¥229,264 million |
| Net assets | ¥191,845 million |
| Full-year earnings forecast | Net Sales ¥142,000 million (YoY +1.6%) / Operating profit ¥25,500 million (YoY -4.2%) / Ordinary income ¥25,500 million (YoY -6.7%) / Net income ¥17,700 million (YoY -5.8%) |
| Revision to Earnings Forecast | No |
| Annual Dividend Forecast | ¥230 → ¥230（0.0%） |
| Segment revenue | Physiological measuring equipment ¥4,526 million (YoY +1.5%) / Patient Monitoring Systems ¥1,301 million (YoY -0.7%) / Treatment equipment ¥15,612 million (YoY +1.7%) / Consumables and other products ¥9,546 million (YoY +3.0%) |
| Segment profit | Physiological measuring equipment ¥587 million / Patient Monitoring Systems ¥194 million / Treatment equipment ¥2,545 million / Consumables and other products ¥1,265 million |
| Regional sales | Domestic ¥30,529 million / Overseas expansion ¥456 million |
| Depreciation and amortization | ¥3,095 million |
| Impairment loss | ¥1 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥0 million, Gain on sale of investment securities ¥78 million, Insurance surrender value ¥1 million / Extraordinary loss Loss on sale of fixed assets ¥0 million, Impairment Losses ¥1 million |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Not disclosed / Excluded Not disclosed / Company name Not disclosed / Material changes No |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | Whether applicable No / Subject person Not disclosed |
| Issued Shares at Period-End | 37,747,300 Shares |
| Treasury Shares at Period-End | 10,729,506 Shares |
| Factors Behind Changes in Business Performance | Although sales of electrocardiograph-related products and automated hematology analyzers declined, sales from the rental business for home healthcare grew, and sales of consumables and other products also increased. |
Items this document does not state (9)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodPayout ratioShareholder Return PolicyOrders received and order backlogMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company explained that sales from its rental business for home healthcare grew, while sales of electrocardiograph-related products and automated hematology analyzers declined. It also stated that uncertainty continues due to U.S. trade policy and geopolitical risks centered on Europe and the Middle East.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.